Rank,Term name,P-value,Z-score,Combined score,Overlapping genes,Adjusted p-value,Old p-value,Old adjusted p-value,gene count
1,"GPCRs, Class A Rhodopsin-like WP455",2.782723857494928e-05,7.133596837944664,74.82782987673542,"['P2RY12', 'CX3CR1', 'P2RY13', 'CHRM3', 'CYSLTR1', 'HRH1', 'GPR34', 'GPR65', 'ADRB2']",0.004423488072148784,0,0,9
2,"GPCRs, Other WP117",3.159743793106111e-05,10.604460093896714,109.88802333011992,"['CHRM3', 'ADGRE2', 'P2RY13', 'ADRB2', 'GRM1', 'ADGRL2', 'GPR135']",0.004423488072148784,0,0,7
3,Cytoplasmic Ribosomal Proteins WP477,3.759338304942309e-05,3.8779918776462456,39.51162800134408,"['RPLP1', 'RPL12', 'RPL36A', 'RPS3A', 'RPS16', 'RPS15A', 'RPL18A', 'RPS19', 'RPS29', 'RPL26', 'RPS2', 'RPL39', 'RPS10', 'RPL28', 'RPS13']",0.004423488072148784,0,0,15
4,Vitamin D Receptor Pathway WP2877,6.65606476466977e-05,4.478845196615231,43.074832497265014,"['CDKN1A', 'DUSP10', 'BCL6', 'SPP1', 'PRKCQ', 'ADRB2', 'CD14', 'MXD1', 'JUNB', 'S100A9', 'HIF1A', 'S100A8']",0.0058739771548210725,0,0,12
5,Complement and Coagulation Cascades WP558,0.0002256563397580022,9.07128514056225,76.16702152180373,"['C1QB', 'C1QA', 'SERPINA1', 'C5AR1', 'PLAT', 'C1QC']",0.01589622191122098,0,0,6
6,Oxidative Damage WP3941,0.00029867850548621373,6.69236471460341,54.316187663543325,"['C1QB', 'C1QA', 'CDKN1A', 'C5AR1', 'CYCS', 'TNFRSF1B', 'C1QC']",0.01589622191122098,0,0,7
7,Photodynamic therapy-induced unfolded protein response WP3613,0.0003152225308174132,8.3725671918443,67.50157680460694,"['XBP1', 'HSPA5', 'DNAJB11', 'CALR', 'PDIA6', 'HSP90B1']",0.01589622191122098,0,0,6
8,Development and heterogeneity of the ILC family WP3893,0.00045242714361120754,18.086,139.27818470307733,"['NFIL3', 'IL15', 'ZBTB16', 'RORA']",0.018184453946500607,0,0,4
9,Complement system WP2806,0.0004636263045850013,5.195276497695852,39.881185240187676,"['FCGR3A', 'RPS19', 'CD93', 'C5AR1', 'ITGAX', 'SPP1', 'VSIG4', 'CALR']",0.018184453946500607,0,0,8
10,Endochondral Ossification with Skeletal Dysplasias WP4808,0.0011605304027461013,5.08281690140845,34.35414001721312,"['SCIN', 'SPP1', 'ENPP1', 'PLAT', 'IGF1', 'VEGFA', 'FGFR1']",0.03724247565176125,0,0,7
11,Endochondral Ossification WP474,0.0011605304027461013,5.08281690140845,34.35414001721312,"['SCIN', 'SPP1', 'ENPP1', 'PLAT', 'IGF1', 'VEGFA', 'FGFR1']",0.03724247565176125,0,0,7
12,NRF2 pathway WP2884,0.0015654734071899265,3.4351844778855702,22.189804306435132,"['ABCC3', 'DNAJB1', 'HSP90AA1', 'SERPINA1', 'FTH1', 'HMOX1', 'NRG1', 'SLC5A3', 'FTL', 'HSPA1A']",0.04605100939483701,0,0,10
13,Nuclear Receptors Meta-Pathway WP2882,0.002008637344742024,2.3758483941251156,14.754728252244712,"['ABCC3', 'CPT1A', 'HSP90AA1', 'SERPINA1', 'NRG1', 'SLC5A3', 'SLC7A5', 'DNAJB1', 'FTH1', 'PDE4B', 'HMOX1', 'JUNB', 'PLTP', 'CPEB4', 'HSPA1A', 'FKBP5', 'FTL']",0.054542229437994964,0,0,17
14,Macrophage markers WP4146,0.0025914716820515907,18.05189620758483,107.50859764475967,"['CD163', 'CD14', 'CD68']",0.0595806108652265,0,0,3
15,Monoamine GPCRs WP58,0.0025914716820515907,18.05189620758483,107.50859764475967,"['CHRM3', 'HRH1', 'ADRB2']",0.0595806108652265,0,0,3
16,Extracellular vesicles in the crosstalk of cardiac cells WP4300,0.002700537602956442,9.039,53.45939759440357,"['CD63', 'SPP1', 'HSPB1', 'IGF1']",0.0595806108652265,0,0,4
17,Apoptosis-related network due to altered Notch3 in ovarian cancer WP2864,0.0033090548419082324,4.09631985461154,23.394462322767314,"['CDKN1A', 'HSPA5', 'HSPB1', 'NRG1', 'APOE', 'YBX3', 'HSPD1']",0.06871155054080036,0,0,7
18,Complement Activation WP545,0.004358046178983578,13.5374251497006,73.58580758606355,"['C1QB', 'C1QA', 'C1QC']",0.07325668100862871,0,0,3
19,FGF23 signaling in hypophosphatemic rickets and related disorders WP4790,0.004358046178983578,13.5374251497006,73.58580758606355,"['CDKN1A', 'SPP1', 'ENPP1']",0.07325668100862871,0,0,3
20,Genes targeted by miRNAs in adipocytes WP1992,0.004358046178983578,13.5374251497006,73.58580758606355,"['TMSB4X', 'IGF1', 'KCNJ2']",0.07325668100862871,0,0,3
21,"GPCRs, Class C Metabotropic glutamate, pheromone WP501",0.004358046178983578,13.5374251497006,73.58580758606355,"['GRM5', 'GRM7', 'GRM1']",0.07325668100862871,0,0,3
22,Lung fibrosis WP3624,0.006114893929121864,5.026163437987085,25.618495052268397,"['CEBPB', 'SERPINA1', 'SPP1', 'HMOX1', 'IGF1']",0.09811625259000083,0,0,5
23,Regulatory circuits of the STAT3 signaling pathway WP4538,0.007652499678832426,3.4297677959649793,16.71230818093425,"['PTPRT', 'IFNAR2', 'DEPTOR', 'IL3RA', 'IL21R', 'JAK3', 'CSF2RA']",0.11744923420121071,0,0,7
24,Statin inhibition of cholesterol production WP430,0.008392157633488686,6.023333333333333,28.79428975693566,"['APOC2', 'APOC1', 'APOE', 'PLTP']",0.12343465185922943,0,0,4
25,LncRNA-mediated mechanisms of therapeutic resistance WP3672,0.015530164070616545,18.01792828685259,75.04415018443885,"['CDKN1A', 'HIF1A']",0.2108518429587554,0,0,2
26,MicroRNA for Targeting Cancer Growth and Vascularization in Glioblastoma WP3593,0.015530164070616545,18.01792828685259,75.04415018443885,"['HIF1A', 'VEGFA']",0.2108518429587554,0,0,2
27,Allograft Rejection WP2328,0.01745044442223764,3.193834160170092,12.929886794161876,"['C1QB', 'C1QA', 'HLA-DRB5', 'HLA-DPA1', 'VEGFA', 'C1QC']",0.2211264235489,0,0,6
28,IL1 and megakaryocytes in obesity WP2865,0.01753977297271728,6.765718562874252,27.355723207265143,"['NLRP3', 'PLA2G7', 'S100A9']",0.2211264235489,0,0,3
29,Toll-like Receptor Signaling Pathway WP75,0.020360825511194905,2.543859649122807,9.906152081506422,"['IFNAR2', 'TICAM2', 'SPP1', 'LY96', 'MAP3K8', 'CD14', 'IKBKE', 'MAP2K6']",0.2397426242384278,0,0,8
30,MAPK Signaling Pathway WP382,0.020651212419836522,1.8965149965916837,7.35844262422473,"['HSPA6', 'CACNA2D3', 'CACNA1B', 'HSPB1', 'CACNA1C', 'FGF14', 'DUSP10', 'MKNK2', 'FGF20', 'MAP3K8', 'CD14', 'HSPA1B', 'HSPA1A', 'MAP2K6', 'FGFR1']",0.2397426242384278,0,0,15
31,Host-pathogen interaction of human coronaviruses - MAPK signaling WP4877,0.02185126222206831,3.476568521658702,13.292647892708283,"['IFITM3', 'BST2', 'IFITM2', 'JUNB', 'MAP2K6']",0.2397426242384278,0,0,5
32,VEGFA-VEGFR2 Signaling Pathway WP3888,0.022211762836010847,1.5914134982717847,6.058723280293614,"['HSPB1', 'ADRB2', 'LDB2', 'STIP1', 'SDCBP', 'RPL18A', 'TMSB4X', 'DNAJB4', 'IER5', 'TMSB10', 'CLIC1', 'MAP2K6', 'TXNDC5', 'PTPN1', 'HSP90AA1', 'SDF2L1', 'PDIA6', 'VEGFA', 'TXNIP', 'CYCS', 'HYOU1', 'PRKD1', 'RPL26', 'CALR', 'PFN1', 'HSPA1A']",0.2397426242384278,0,0,26
33,TYROBP causal network in microglia WP3945,0.022545343686038447,2.6970332634102485,10.227761613728562,"['DPYD', 'ITGAX', 'SPP1', 'TCIRG1', 'TNFRSF1B', 'GAL3ST4', 'C1QC']",0.2397426242384278,0,0,7
34,IL-18 signaling pathway WP4754,0.02309135757537265,1.9149301825993554,7.216025398794785,"['SPON1', 'CPT1A', 'CEBPB', 'NRN1', 'TICAM2', 'TNFAIP2', 'HSPB1', 'PLA2G7', 'VEGFA', 'GRM7', 'TMSB4X', 'SPP1', 'HMOX1', 'CYCS']",0.2397426242384278,0,0,14
35,Eicosanoid metabolism via lipooxygenases (LOX) WP4721,0.028110156463364212,5.411377245508982,19.327406617876438,"['CYSLTR1', 'LTC4S', 'ALOX15B']",0.2835110066162162,0,0,3
36,Focal Adhesion-PI3K-Akt-mTOR-signaling pathway WP3932,0.0327544086416683,1.8177551020408163,6.21439156151283,"['IFNAR2', 'CDKN1A', 'HSP90AA1', 'IGF1', 'HIF1A', 'VEGFA', 'HSP90B1', 'FGF14', 'IL3RA', 'SPP1', 'FGF20', 'ITGAX', 'JAK3', 'FGFR1']",0.3195659860258581,0,0,14
37,Calcium Regulation in the Cardiac Cell WP536,0.033495584937554536,2.0608667648141332,6.9994076114273325,"['CHRM3', 'RYR2', 'CACNA1B', 'PRKCQ', 'PRKD1', 'CACNA1C', 'ADRB2', 'CALR', 'RGS6', 'RGS7']",0.3195659860258581,0,0,10
38,"Metabolic pathway of LDL, HDL and TG, including diseases WP4522",0.03618122554110663,9.006972111553784,29.89607627206241,"['LIPG', 'APOE']",0.3361045425265958,0,0,2
39,Fibrin Complement Receptor 3 Signaling Pathway WP4136,0.04015367596458304,3.4384761904761905,11.054842916747226,"['TICAM2', 'LY96', 'PLAT', 'CD14']",0.363442246551226,0,0,4
40,Immune response to tuberculosis WP4197,0.04136853743221324,4.508483033932135,14.360576389782764,"['IFNAR2', 'OAS1', 'PTPN2']",0.36507734283928184,0,0,3
41,Nucleotide-binding Oligomerization Domain (NOD) pathway WP1433,0.0455461796237872,3.2818181818181817,10.1376299969901,"['HSP90AA1', 'CASP1', 'NLRP3', 'NLRP1']",0.3678596621781236,0,0,4
42,Activation of NLRP3 Inflammasome by SARS-CoV-2 WP4876,0.0489105212289198,7.2047808764940235,21.742319333624323,"['CASP1', 'NLRP3']",0.3678596621781236,0,0,2
43,Caloric restriction and aging WP4191,0.0489105212289198,7.2047808764940235,21.742319333624323,"['NAMPT', 'IGF1']",0.3678596621781236,0,0,2
44,"GPCRs, Class B Secretin-like WP334",0.0489105212289198,7.2047808764940235,21.742319333624323,"['ADGRE2', 'ADGRL2']",0.3678596621781236,0,0,2
45,STING pathway in Kawasaki-like disease and COVID-19 WP4961,0.048978481933064616,4.161216029479503,12.55178476160907,"['FCGR2A', 'NLRP3', 'IKBKE']",0.3678596621781236,0,0,3
46,Type I collagen synthesis in the context of Osteogenesis imperfecta WP4786,0.048978481933064616,4.161216029479503,12.55178476160907,"['P4HA1', 'PLOD1', 'PPIB']",0.3678596621781236,0,0,3
47,Fluoropyrimidine Activity WP1601,0.048978481933064616,4.161216029479503,12.55178476160907,"['ABCC3', 'DPYD', 'TYMP']",0.3678596621781236,0,0,3
48,Codeine and Morphine Metabolism WP1604,0.05276912575435184,inf,inf,['ABCC3'],0.38807294565179584,0,0,1
49,Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways WP706,0.0559263757154231,2.0390731485688325,5.880114332894781,"['RYR2', 'CPT1A', 'CEBPB', 'RORA', 'HIF1A', 'HSP90B1', 'HSPD1', 'VEGFA']",0.40289817607233375,0,0,8
50,Regulation of Actin Cytoskeleton WP51,0.06268428073211164,1.8945031712473572,5.247100418823785,"['GNA13', 'CHRM3', 'FGF14', 'TMSB4X', 'FGF20', 'CD14', 'PFN1', 'PAK5', 'FGFR1']",0.4345450288295859,0,0,9
51,Leptin and adiponectin WP3934,0.06298024080326348,6.00332005312085,16.598785167524323,"['CPT1A', 'LEPR']",0.4345450288295859,0,0,2
52,Disruption of postsynaptic signaling by CNV WP4875,0.06401229886441492,2.88704,7.935549235177357,"['RYR2', 'NRXN3', 'DLGAP1', 'GRM1']",0.4345450288295859,0,0,4
53,Apoptosis Modulation and Signaling WP1772,0.07342834122728902,2.1679518072289157,5.661487552463663,"['CASP4', 'CASP1', 'CYCS', 'PRKD1', 'TNFRSF1B', 'HSPA1A']",0.4679587588655149,0,0,6
54,Photodynamic therapy-induced AP-1 survival signaling. WP3611,0.07818601138018605,2.6725925925925926,6.811541943984617,"['CDKN1A', 'HSP90AA1', 'JUNB', 'MAP2K6']",0.4679587588655149,0,0,4
55,Galanin receptor pathway WP4970,0.07821407017865546,5.14513375071144,13.111373777687996,"['CDKN1A', 'VEGFA']",0.4679587588655149,0,0,2
56,NOTCH1 regulation of endothelial cell calcification WP3413,0.07821407017865546,5.14513375071144,13.111373777687996,"['PLAT', 'VEGFA']",0.4679587588655149,0,0,2
57,Omega-3/Omega-6 FA synthesis WP4723,0.07821407017865546,5.14513375071144,13.111373777687996,"['ACSL1', 'ELOVL5']",0.4679587588655149,0,0,2
58,Peptide GPCRs WP24,0.07821407017865546,5.14513375071144,13.111373777687996,"['CX3CR1', 'C5AR1']",0.4679587588655149,0,0,2
59,Pyrimidine metabolism and related diseases WP4225,0.07821407017865546,5.14513375071144,13.111373777687996,"['DPYD', 'TYMP']",0.4679587588655149,0,0,2
60,Cardiac Hypertrophic Response WP2795,0.09333548579836631,2.200987340534728,5.219762318053147,"['NRG1', 'PRKD1', 'IGF1', 'IKBKE', 'MAP2K6']",0.4710900468561892,0,0,5
61,The Overlap Between Signal Transduction Pathways that Contribute to a Range of LMNA Laminopathies WP4879,0.09378316142888578,2.4877241379310346,5.887870745407161,"['CDKN1A', 'CEBPB', 'SPP1', 'JUNB']",0.4710900468561892,0,0,4
62,Microglia Pathogen Phagocytosis Pathway WP3937,0.09378316142888578,2.4877241379310346,5.887870745407161,"['C1QB', 'C1QA', 'FCER1G', 'C1QC']",0.4710900468561892,0,0,4
63,PPAR signaling pathway WP3942,0.09378316142888578,2.4877241379310346,5.887870745407161,"['CPT1A', 'ACSL1', 'OLR1', 'PLTP']",0.4710900468561892,0,0,4
64,Biomarkers for pyrimidine metabolism disorders WP4584,0.09445050767309925,4.501494023904383,10.622082312309393,"['DPYD', 'TYMP']",0.4710900468561892,0,0,2
65,Iron metabolism in placenta WP2007,0.09445050767309925,4.501494023904383,10.622082312309393,"['FTH1', 'HAMP']",0.4710900468561892,0,0,2
66,"NAD metabolism, sirtuins and aging WP3630",0.09445050767309925,4.501494023904383,10.622082312309393,"['NAMPT', 'HIF1A']",0.4710900468561892,0,0,2
67,PPAR-alpha pathway WP2878,0.09445050767309925,4.501494023904383,10.622082312309393,"['CPT1A', 'PLTP']",0.4710900468561892,0,0,2
68,Aryl Hydrocarbon Receptor Pathway WP2873,0.09599681203319495,3.0036593479707254,7.038896351651632,"['SLC7A5', 'HSP90AA1', 'JUNB']",0.4710900468561892,0,0,3
69,Unfolded protein response WP4925,0.09599681203319495,3.0036593479707254,7.038896351651632,"['XBP1', 'HSPA5', 'TXNIP']",0.4710900468561892,0,0,3
70,Regulation of toll-like receptor signaling pathway WP1449,0.09692448515237811,1.7853444842692154,4.1666782117955545,"['IFNAR2', 'TICAM2', 'SPP1', 'LY96', 'MAP3K8', 'CD14', 'IKBKE', 'MAP2K6']",0.4710900468561892,0,0,8
71,Ferroptosis WP4313,0.10209170044559909,2.404533333333333,5.486865769543448,"['ACSL1', 'FTH1', 'HMOX1', 'FTL']",0.4710900468561892,0,0,4
72,Blood Clotting Cascade WP272,0.10275901871933872,17.98409542743539,40.92044704270068,['PLAT'],0.4710900468561892,0,0,1
73,Catalytic cycle of mammalian Flavin-containing MonoOxygenases (FMOs) WP688,0.10275901871933872,17.98409542743539,40.92044704270068,['FMO5'],0.4710900468561892,0,0,1
74,Composition of Lipid Particles WP3601,0.10275901871933872,17.98409542743539,40.92044704270068,['APOE'],0.4710900468561892,0,0,1
75,Drug Induction of Bile Acid Pathway WP2289,0.10275901871933872,17.98409542743539,40.92044704270068,['ABCC3'],0.4710900468561892,0,0,1
76,Hfe effect on hepcidin production WP3924,0.10275901871933872,17.98409542743539,40.92044704270068,['HAMP'],0.4710900468561892,0,0,1
77,SARS-CoV-2 altering angiogenesis via NRP1 WP5065,0.10275901871933872,17.98409542743539,40.92044704270068,['VEGFA'],0.4710900468561892,0,0,1
78,Eicosanoid Synthesis WP167,0.1115417966717083,4.000885347498893,8.775365483286334,"['LTC4S', 'ALOX15B']",0.4921781778139128,0,0,2
79,Omega-9 FA synthesis WP4724,0.1115417966717083,4.000885347498893,8.775365483286334,"['ACSL1', 'ELOVL5']",0.4921781778139128,0,0,2
80,Phytochemical activity on NRF2 transcriptional activation WP3,0.1115417966717083,4.000885347498893,8.775365483286334,"['CEBPB', 'HMOX1']",0.4921781778139128,0,0,2
81,Oncostatin M Signaling Pathway WP2374,0.11457476514762381,2.050236837310986,4.441894896229922,"['CEBPB', 'JAK3', 'JUNB', 'HIF1A', 'VEGFA']",0.4993196555198914,0,0,5
82,Bladder cancer WP2828,0.11847811951124411,2.702694610778443,5.764920526006575,"['CDKN1A', 'TYMP', 'VEGFA']",0.5002731347696205,0,0,3
83,PI3K-Akt signaling pathway WP4172,0.1258353290271448,1.4973927670311187,3.103767485579269,"['IFNAR2', 'CDKN1A', 'HSP90AA1', 'FGF14', 'IL3RA', 'SPP1', 'FGF20', 'IGF1', 'JAK3', 'VEGFA', 'HSP90B1', 'FGFR1']",0.5002731347696205,0,0,12
84,Adipogenesis WP236,0.12703892849638995,1.8354094343475598,3.7869300188885777,"['CDKN1A', 'CEBPB', 'NAMPT', 'RORA', 'IGF1', 'HIF1A']",0.5002731347696205,0,0,6
85,Endoplasmic reticulum stress response in coronavirus infection WP4861,0.12892018147852422,2.185212121212121,4.476542107775693,"['PPP1R14B', 'XBP1', 'HSPA5', 'PPP1R3B']",0.5002731347696205,0,0,4
86,Glucocorticoid Receptor Pathway WP2880,0.12892018147852422,2.185212121212121,4.476542107775693,"['HSP90AA1', 'MGAM', 'PDE4B', 'CPEB4']",0.5002731347696205,0,0,4
87,Genes controlling nephrogenesis WP4823,0.1293529293134708,3.600398406374502,7.36357343208782,"['ROBO2', 'VEGFA']",0.5002731347696205,0,0,2
88,Kallmann's Syndrome WP5074,0.1293529293134708,3.600398406374502,7.36357343208782,"['PRKCQ', 'FGFR1']",0.5002731347696205,0,0,2
89,Mitochondrial LC-Fatty Acid Beta-Oxidation WP368,0.1293529293134708,3.600398406374502,7.36357343208782,"['CPT1A', 'ACSL1']",0.5002731347696205,0,0,2
90,Pregnane X receptor pathway WP2876,0.1293529293134708,3.600398406374502,7.36357343208782,"['ABCC3', 'HSP90AA1']",0.5002731347696205,0,0,2
91,Type 2 papillary renal cell carcinoma WP4241,0.13038279999661498,2.5737097234103223,5.243368735256374,"['CDKN1A', 'HIF1A', 'VEGFA']",0.5002731347696205,0,0,3
92,Type I interferon induction and signaling during SARS-CoV-2 infection WP4868,0.13038279999661498,2.5737097234103223,5.243368735256374,"['IFNAR2', 'OAS1', 'IKBKE']",0.5002731347696205,0,0,3
93,Apoptosis WP254,0.1378999443944758,1.918731079179636,3.8014416229743864,"['CASP4', 'CASP1', 'CYCS', 'IGF1', 'TNFRSF1B']",0.517858301821808,0,0,5
94,MECP2 and Associated Rett Syndrome WP3584,0.1378999443944758,1.918731079179636,3.8014416229743864,"['MPP1', 'RBFOX1', 'BCL6', 'IGF1', 'FKBP5']",0.517858301821808,0,0,5
95,TNF-alpha signaling pathway WP231,0.14099294344452304,1.774837053130555,3.4769864291986647,"['HSP90AA1', 'MAP3K8', 'PYGL', 'KSR2', 'TNFRSF1B', 'MAP2K6']",0.523900095114912,0,0,6
96,Cardiac Progenitor Differentiation WP2406,0.14776071671864094,3.272727272727273,6.257981757415499,"['NRG1', 'IGF1']",0.5299083650231565,0,0,2
97,Constitutive Androstane Receptor Pathway WP2875,0.14776071671864094,3.272727272727273,6.257981757415499,"['ABCC3', 'HSP90AA1']",0.5299083650231565,0,0,2
98,Differentiation Pathway WP2848,0.14776071671864094,3.272727272727273,6.257981757415499,"['IGF1', 'VEGFA']",0.5299083650231565,0,0,2
99,Linoleic acid metabolism known to be affected by coronavirus infection WP4853,0.15011568414253726,8.991053677932406,17.050176141215253,['ELOVL5'],0.5299083650231565,0,0,1
100,Nephrogenesis WP5052,0.15011568414253726,8.991053677932406,17.050176141215253,['FGF20'],0.5299083650231565,0,0,1
101,Fatty acid beta-oxidation WP143,0.155357294781469,2.3493881801614163,4.374625839373741,"['CPT1A', 'GK', 'ACSL1']",0.5429814362164214,0,0,3
102,Parkin-Ubiquitin Proteasomal System pathway WP2359,0.1631245581011975,1.803006012024048,3.2692848026400045,"['HSPA5', 'HSPA6', 'CASP1', 'HSPA1B', 'HSPA1A']",0.5645389118600267,0,0,5
103,Apoptosis Modulation by HSP70 WP384,0.1666529216069345,2.999667994687915,5.374930927918456,"['CYCS', 'HSPA1A']",0.5656584743004603,0,0,2
104,Photodynamic therapy-induced NFE2L2 (NRF2) survival signaling WP3612,0.1666529216069345,2.999667994687915,5.374930927918456,"['ABCC3', 'HMOX1']",0.5656584743004603,0,0,2
105,Prion disease pathway WP3995,0.16836170328450062,2.25124750499002,4.0109139965382745,"['HSPA5', 'HSP90B1', 'FGFR1']",0.5660160119945592,0,0,3
106,NO/cGMP/PKG mediated Neuroprotection WP4008,0.1816676555312112,2.1609580838323352,3.685678957281522,"['TSPO', 'CYCS', 'PPID']",0.5791670307763744,0,0,3
107,"4-hydroxytamoxifen, Dexamethasone, and Retinoic Acids Regulation of p27 Expression WP3879",0.1859274491919997,2.76861783634692,4.657919157941215,"['MKNK2', 'MAP2K6']",0.5791670307763744,0,0,2
108,Angiogenesis WP1539,0.1859274491919997,2.76861783634692,4.657919157941215,"['HIF1A', 'VEGFA']",0.5791670307763744,0,0,2
109,Vitamin B12 metabolism WP1533,0.1859274491919997,2.76861783634692,4.657919157941215,"['PLAT', 'APOE']",0.5791670307763744,0,0,2
110,White fat cell differentiation WP4149,0.1859274491919997,2.76861783634692,4.657919157941215,"['CEBPB', 'RORA']",0.5791670307763744,0,0,2
111,Hereditary leiomyomatosis and renal cell carcinoma pathway WP4206,0.1859274491919997,2.76861783634692,4.657919157941215,"['HIF1A', 'VEGFA']",0.5791670307763744,0,0,2
112,Pre-implantation embryo WP3527,0.1859274491919997,2.76861783634692,4.657919157941215,"['ZFP36', 'MXD1']",0.5791670307763744,0,0,2
113,Association Between Physico-Chemical Features and Toxicity Associated Pathways WP3680,0.1899334911591725,1.8477948717948718,3.0693375348129748,"['CDKN1A', 'TMSB4X', 'PFN1', 'PFN2']",0.5791670307763744,0,0,4
114,miR-509-3p alteration of YAP1/ECM axis WP3967,0.19497755207845022,5.993373094764745,9.798390933389008,['GPC6'],0.5791670307763744,0,0,1
115,miR-517 relationship with ARCN1 and USP1 WP3596,0.19497755207845022,5.993373094764745,9.798390933389008,['CDKN1A'],0.5791670307763744,0,0,1
116,Robo4 and VEGF Signaling Pathways Crosstalk WP3943,0.19497755207845022,5.993373094764745,9.798390933389008,['VEGFA'],0.5791670307763744,0,0,1
117,Aryl Hydrocarbon Receptor Netpath WP2586,0.19524327666399025,2.0776140027637036,3.3938010169562736,"['CDKN1A', 'HSP90AA1', 'VEGFA']",0.5791670307763744,0,0,3
118,Hepatitis C and Hepatocellular Carcinoma WP3646,0.19524327666399025,2.0776140027637036,3.3938010169562736,"['CDKN1A', 'HIF1A', 'VEGFA']",0.5791670307763744,0,0,3
119,Host-pathogen interaction of human coronaviruses - interferon induction WP4880,0.19524327666399025,2.0776140027637036,3.3938010169562736,"['IFNAR2', 'OAS1', 'IKBKE']",0.5791670307763744,0,0,3
120,IL-4 signaling pathway WP395,0.20088583494606987,1.8014,2.8912803576600816,"['CEBPB', 'HRH1', 'NFIL3', 'JAK3']",0.5909391644663556,0,0,4
121,Mammary gland development pathway - Pregnancy and lactation (Stage 3 of 4) WP2817,0.2054915927060843,2.57057484348321,4.067549507907925,"['PTPN1', 'CEBPB']",0.5945781329938341,0,0,2
122,SARS coronavirus and innate immunity WP4912,0.2054915927060843,2.57057484348321,4.067549507907925,"['IFNAR2', 'IKBKE']",0.5945781329938341,0,0,2
123,Fas ligand pathway and stress induction of heat shock proteins WP314,0.209057309156486,2.0004435573297847,3.130987948590488,"['HSPB1', 'CYCS', 'LMNB1']",0.5999774807499151,0,0,3
124,NRF2-ARE regulation WP4357,0.22526133012237592,2.398937583001328,3.575602274265323,"['CEBPB', 'HMOX1']",0.6412681413967637,0,0,2
125,Hippo-Merlin Signaling Dysregulation WP4541,0.22812224079439364,1.580353689835812,2.3355630756774706,"['ITGAX', 'CDH12', 'CDH18', 'PAK5', 'FGFR1']",0.6442172080033676,0,0,5
126,Thiamine metabolic pathways WP4297,0.23747579922454218,4.494532803180914,6.461742882373788,['SLC25A19'],0.6448381317404877,0,0,1
127,Folate-Alcohol and Cancer Pathway Hypotheses WP1589,0.23747579922454218,4.494532803180914,6.461742882373788,['CEBPB'],0.6448381317404877,0,0,1
128,GDNF/RET signaling axis WP4830,0.23747579922454218,4.494532803180914,6.461742882373788,['ROBO2'],0.6448381317404877,0,0,1
129,Inflammatory Response Pathway WP453,0.23747579922454218,4.494532803180914,6.461742882373788,['TNFRSF1B'],0.6448381317404877,0,0,1
130,PTF1A related regulatory pathway WP4147,0.23747579922454218,4.494532803180914,6.461742882373788,['PROX1'],0.6448381317404877,0,0,1
131,Purinergic signaling WP4900,0.24516066865789596,2.2487549800796813,3.161393058437099,"['P2RY12', 'P2RY13']",0.6606237865361624,0,0,2
132,Circadian rhythm related genes WP3594,0.2610519077764942,1.3476032559541755,1.8098797013733026,"['CPT1A', 'PER3', 'KCND2', 'NFIL3', 'KCNH7', 'NAMPT', 'RORA', 'PROX1']",0.6981160867053215,0,0,8
133,NAD Metabolism in Oncogene-Induced Senescence and Mitochondrial Dysfunction-Associated Senescence WP5046,0.26512103414524474,2.116240918678228,2.8094554690709646,"['SCO2', 'NAMPT']",0.7036671056636947,0,0,2
134,Farnesoid X receptor pathway WP2879,0.27773472042265324,3.5952286282306165,4.605807358999383,['FKBP5'],0.7071538813854159,0,0,1
135,HIF1A and PPARG regulation of glycolysis WP2456,0.27773472042265324,3.5952286282306165,4.605807358999383,['HIF1A'],0.7071538813854159,0,0,1
136,Major receptors targeted by epinephrine and norepinephrine WP4589,0.27773472042265324,3.5952286282306165,4.605807358999383,['ADRB2'],0.7071538813854159,0,0,1
137,Nanomaterial-induced inflammasome activation WP3890,0.27773472042265324,3.5952286282306165,4.605807358999383,['CASP1'],0.7071538813854159,0,0,1
138,Pathogenesis of SARS-CoV-2 Mediated by nsp9-nsp10 Complex WP4884,0.27773472042265324,3.5952286282306165,4.605807358999383,['HLA-DRB5'],0.7071538813854159,0,0,1
139,Senescence and Autophagy in Cancer WP615,0.2784543612254187,1.4520977438748464,1.8565085723785453,"['CDKN1A', 'CEBPB', 'PLAT', 'IGF1', 'ATG14']",0.7071538813854159,0,0,5
140,G13 Signaling Pathway WP524,0.2806667468709748,1.686938622754491,2.143402735369423,"['GNA13', 'IQGAP2', 'PFN1']",0.7076811546103865,0,0,3
141,Oxidative Stress WP408,0.28508070217021114,1.9984506418769368,2.5080215285115504,"['HMOX1', 'JUNB']",0.7137126799013087,0,0,2
142,Ectoderm Differentiation WP2858,0.29167375264991957,1.3676986426719537,1.6851680129197777,"['SDCBP', 'PTPRB', 'PLCXD3', 'ZBTB16', 'PIM1', 'LDB2']",0.7241950287377422,0,0,6
143,Neurodegeneration with brain iron accumulation (NBIA) subtypes pathway WP4577,0.2953025753948509,1.6356378152785338,1.9950770255220496,"['DEPTOR', 'ATG14', 'FTL']",0.7241950287377422,0,0,3
144,The influence of laminopathies on Wnt signaling WP4844,0.3049842685065335,1.8930593415810442,2.2479986587659684,"['CEBPB', 'SPP1']",0.7241950287377422,0,0,2
145,Melatonin metabolism and effects WP3298,0.3049842685065335,1.8930593415810442,2.2479986587659684,"['PER3', 'APOE']",0.7241950287377422,0,0,2
146,Thyroid hormones production and their peripheral downstream signaling effects WP4746,0.3058803407258028,1.4690612244897958,1.7401930692878695,"['NHSL1', 'PRKCQ', 'MGLL', 'FGFR1']",0.7241950287377422,0,0,4
147,Amplification and Expansion of Oncogenic Pathways as Metastatic Traits WP3678,0.3158720875544197,2.9956925115970843,3.4522897738062817,['VEGFA'],0.7241950287377422,0,0,1
148,ApoE and miR-146 in inflammation and atherosclerosis WP3926,0.3158720875544197,2.9956925115970843,3.4522897738062817,['APOE'],0.7241950287377422,0,0,1
149,Aspirin and miRNAs WP4707,0.3158720875544197,2.9956925115970843,3.4522897738062817,['VEGFA'],0.7241950287377422,0,0,1
150,Transcriptional cascade regulating adipogenesis WP4211,0.3158720875544197,2.9956925115970843,3.4522897738062817,['CEBPB'],0.7241950287377422,0,0,1
151,Cytokines and Inflammatory Response WP530,0.3158720875544197,2.9956925115970843,3.4522897738062817,['IL15'],0.7241950287377422,0,0,1
152,Differentiation of white and brown adipocyte WP2895,0.3158720875544197,2.9956925115970843,3.4522897738062817,['CEBPB'],0.7241950287377422,0,0,1
153,Ethanol metabolism resulting in production of ROS by CYP2E1 WP4269,0.3158720875544197,2.9956925115970843,3.4522897738062817,['PRKCQ'],0.7241950287377422,0,0,1
154,Spinal Cord Injury WP2431,0.31798931856756385,1.43952,1.6493120261004695,"['C1QB', 'ZFP36', 'FCGR2A', 'LILRB3']",0.7241950287377422,0,0,4
155,Pyrimidine metabolism WP4022,0.31798931856756385,1.43952,1.6493120261004695,"['DPYD', 'ENPP1', 'POLR2K', 'TYMP']",0.7241950287377422,0,0,4
156,Arrhythmogenic Right Ventricular Cardiomyopathy WP2118,0.3393877493370374,1.4988356620093146,1.6196598352081257,"['RYR2', 'CACNA2D3', 'CACNA1C']",0.744847683316964,0,0,3
157,Photodynamic therapy-induced HIF-1 survival signaling WP3614,0.34443015675632316,1.7123885410738,1.8251732093411583,"['HIF1A', 'VEGFA']",0.744847683316964,0,0,2
158,Fatty acid transporters WP5061,0.3519994906467896,2.5674524282874183,2.680742679840308,['ACSL1'],0.744847683316964,0,0,1
159,Hypertrophy Model WP516,0.3519994906467896,2.5674524282874183,2.680742679840308,['VEGFA'],0.744847683316964,0,0,1
160,IL-10 Anti-inflammatory Signaling Pathway  WP4495,0.3519994906467896,2.5674524282874183,2.680742679840308,['HMOX1'],0.744847683316964,0,0,1
161,Mammary gland development pathway - Embryonic development (Stage 1 of 4) WP2813,0.3519994906467896,2.5674524282874183,2.680742679840308,['NRG3'],0.744847683316964,0,0,1
162,Nanoparticle triggered regulated necrosis WP2513,0.3519994906467896,2.5674524282874183,2.680742679840308,['FTL'],0.744847683316964,0,0,1
163,Nuclear Receptors in Lipid Metabolism and Toxicity WP299,0.3519994906467896,2.5674524282874183,2.680742679840308,['ABCC3'],0.744847683316964,0,0,1
164,Osteoclast Signaling WP12,0.3519994906467896,2.5674524282874183,2.680742679840308,['SPP1'],0.744847683316964,0,0,1
165,RalA downstream regulated genes WP2290,0.3519994906467896,2.5674524282874183,2.680742679840308,['YBX3'],0.744847683316964,0,0,1
166,Cytosolic DNA-sensing pathway WP4655,0.35406816654508827,1.4581647515779252,1.5139626266307151,"['CASP1', 'IKBKE', 'POLR2K']",0.744847683316964,0,0,3
167,ESC Pluripotency Pathways WP3931,0.35448841585623214,1.3575849056603773,1.4079236258064787,"['FGF14', 'FGF20', 'MAP2K6', 'FGFR1']",0.744847683316964,0,0,4
168,Pathways in clear cell renal cell carcinoma WP4018,0.35448841585623214,1.3575849056603773,1.4079236258064787,"['DEPTOR', 'HIF1A', 'KCNJ2', 'VEGFA']",0.744847683316964,0,0,4
169,Vitamin D-sensitive calcium signaling in depression WP4698,0.3638890035993311,1.6343716044911265,1.6521967035410383,"['GRM5', 'CACNA1C']",0.7539823904321152,0,0,2
170,Toll-like Receptor Signaling related to MyD88 WP3858,0.38312397526305486,1.5631387493504243,1.4996700748845586,"['TICAM2', 'IKBKE']",0.7539823904321152,0,0,2
171,Notch Signaling Pathway Netpath WP61,0.38328626700419044,1.383079993858437,1.326336558439961,"['CDKN1A', 'HIF1A', 'SAP30']",0.7539823904321152,0,0,3
172,Tryptophan catabolism leading to NAD+ production WP4210,0.38622266146667467,2.246272365805169,2.1369715213515197,['NAMPT'],0.7539823904321152,0,0,1
173,Cell-type Dependent Selectivity of CCK2R Signaling WP3679,0.38622266146667467,2.246272365805169,2.1369715213515197,['RYR2'],0.7539823904321152,0,0,1
174,Leptin Insulin Overlap WP3935,0.38622266146667467,2.246272365805169,2.1369715213515197,['LEPR'],0.7539823904321152,0,0,1
175,LTF danger signal response pathway WP4478,0.38622266146667467,2.246272365805169,2.1369715213515197,['CD14'],0.7539823904321152,0,0,1
176,MFAP5-mediated ovarian cancer cell motility and invasiveness WP3301,0.38622266146667467,2.246272365805169,2.1369715213515197,['PRKCQ'],0.7539823904321152,0,0,1
177,ncRNAs involved in STAT3 signaling in hepatocellular carcinoma WP4337,0.38622266146667467,2.246272365805169,2.1369715213515197,['JAK3'],0.7539823904321152,0,0,1
178,Overview of nanoparticle effects WP3287,0.38622266146667467,2.246272365805169,2.1369715213515197,['HMOX1'],0.7539823904321152,0,0,1
179,Pathways Regulating Hippo Signaling WP4540,0.39098623684204453,1.2844285714285715,1.2061849327576233,"['CDH12', 'PRKCQ', 'CDH18', 'FGFR1']",0.7539823904321152,0,0,4
180,Myometrial relaxation and contraction pathways WP289,0.3958777557147705,1.1990629183400268,1.111111429144434,"['RYR2', 'PDE4B', 'PRKCQ', 'PRKD1', 'RGS6', 'RGS7']",0.7539823904321152,0,0,6
181,Structural Pathway of Interleukin 1 (IL-1) WP2637,0.3977877212355422,1.3483532934131737,1.2429616579201692,"['MKNK2', 'MAP3K8', 'MAP2K6']",0.7539823904321152,0,0,3
182,Hematopoietic Stem Cell Differentiation WP2849,0.4021045267430765,1.4978419654714474,1.3645987483831488,"['SEC14L2', 'PIM1']",0.7539823904321152,0,0,2
183,MicroRNAs in cardiomyocyte hypertrophy WP1544,0.40309821162636916,1.2617543859649123,1.146398548536534,"['NRG1', 'IGF1', 'IKBKE', 'MAP2K6']",0.7539823904321152,0,0,4
184,Modulators of TCR signaling and T cell activation WP5072,0.41219517197410965,1.3153205783554842,1.1657138105304992,"['GNA13', 'MAP3K8', 'PRKCQ']",0.7539823904321152,0,0,3
185,Serotonin and anxiety WP3947,0.41864178052321416,1.9964656505411973,1.7384018293689563,['GRM1'],0.7539823904321152,0,0,1
186,Autosomal recessive Osteopetrosis pathways WP4788,0.41864178052321416,1.9964656505411973,1.7384018293689563,['TCIRG1'],0.7539823904321152,0,0,1
187,Vitamin A and carotenoid metabolism WP716,0.41864178052321416,1.9964656505411973,1.7384018293689563,['BCO2'],0.7539823904321152,0,0,1
188,Development of ureteric collection system WP5053,0.41864178052321416,1.9964656505411973,1.7384018293689563,['ROBO2'],0.7539823904321152,0,0,1
189,Kynurenine Pathway and links to Cellular Senescence WP5044,0.41864178052321416,1.9964656505411973,1.7384018293689563,['CDKN1A'],0.7539823904321152,0,0,1
190,MAPK and NFkB signaling pathways inhibited by Yersinia YopJ WP3849,0.41864178052321416,1.9964656505411973,1.7384018293689563,['MAP2K6'],0.7539823904321152,0,0,1
191,miRNAs involved in DNA damage response WP1545,0.41864178052321416,1.9964656505411973,1.7384018293689563,['CDKN1A'],0.7539823904321152,0,0,1
192,NAD+ metabolism WP3644,0.41864178052321416,1.9964656505411973,1.7384018293689563,['NAMPT'],0.7539823904321152,0,0,1
193,Nanomaterial induced apoptosis WP2507,0.41864178052321416,1.9964656505411973,1.7384018293689563,['CYCS'],0.7539823904321152,0,0,1
194,Osteopontin Signaling WP1434,0.41864178052321416,1.9964656505411973,1.7384018293689563,['SPP1'],0.7539823904321152,0,0,1
195,Ovarian infertility WP34,0.41864178052321416,1.9964656505411973,1.7384018293689563,['CEBPB'],0.7539823904321152,0,0,1
196,Proteoglycan biosynthesis WP4784,0.41864178052321416,1.9964656505411973,1.7384018293689563,['CHSY1'],0.7539823904321152,0,0,1
197,Autophagy WP4923,0.4208039466887419,1.437768924302789,1.244515870685899,"['DEPTOR', 'ATG14']",0.7540294070107912,0,0,2
198,Glioblastoma signaling pathways WP2261,0.4271782234608939,1.2187118644067796,1.0365802117300564,"['CDKN1A', 'PRKCQ', 'MAP2K6', 'FGFR1']",0.761585418594422,0,0,4
199,p38 MAPK Signaling Pathway WP400,0.4391990395092216,1.38231688630095,1.1373738944806355,"['HSPB1', 'MAP2K6']",0.7775547750033064,0,0,2
200,7-oxo-C and 7beta-HC pathways WP5064,0.4493517679905793,1.7966202783300198,1.4372050447855014,['ACOT11'],0.7775547750033064,0,0,1
201,TP53 network WP1742,0.4493517679905793,1.7966202783300198,1.4372050447855014,['CDKN1A'],0.7775547750033064,0,0,1
202,ERK Pathway in Huntington's Disease WP3853,0.4493517679905793,1.7966202783300198,1.4372050447855014,['GRM1'],0.7775547750033064,0,0,1
203,FOXA2 pathway WP5066,0.4493517679905793,1.7966202783300198,1.4372050447855014,['ABCC3'],0.7775547750033064,0,0,1
204,Globo Sphingolipid Metabolism WP1424,0.4493517679905793,1.7966202783300198,1.4372050447855014,['ST6GALNAC5'],0.7775547750033064,0,0,1
205,Factors and pathways affecting insulin-like growth factor (IGF1)-Akt signaling WP3850,0.45726982962293705,1.3309724066696178,1.041461452287102,"['DEPTOR', 'IGF1']",0.7859093397742131,0,0,2
206,Fragile X Syndrome  WP4549,0.4717045343289971,1.1001967051880994,0.82669052836439,"['CPT1A', 'GRM5', 'DEPTOR', 'KCND2', 'GRM1', 'HCN1']",0.7859093397742131,0,0,6
207,Airway smooth muscle cell contraction WP4962,0.47844255917505957,1.6331104283390565,1.2039602309097068,['ADRB2'],0.7859093397742131,0,0,1
208,Wnt/beta-catenin signaling pathway in leukemia WP3658,0.47844255917505957,1.6331104283390565,1.2039602309097068,['ZBTB16'],0.7859093397742131,0,0,1
209,Deregulation of Rab and Rab Effector Genes in Bladder Cancer WP2291,0.47844255917505957,1.6331104283390565,1.2039602309097068,['RAB27A'],0.7859093397742131,0,0,1
210,Imatinib and Chronic Myeloid Leukemia WP3640,0.47844255917505957,1.6331104283390565,1.2039602309097068,['PIM1'],0.7859093397742131,0,0,1
211,"Oligodendrocyte specification and differentiation, leading to myelin components for CNS WP4304",0.47844255917505957,1.6331104283390565,1.2039602309097068,['IGF1'],0.7859093397742131,0,0,1
212,Pathways of nucleic acid metabolism and innate immune sensing WP4705,0.47844255917505957,1.6331104283390565,1.2039602309097068,['OAS1'],0.7859093397742131,0,0,1
213,AMP-activated protein kinase (AMPK) signaling WP1403,0.4823229150860402,1.1717000781046603,0.8543350832933985,"['CDKN1A', 'CPT1A', 'LEPR']",0.7859093397742131,0,0,3
214,MET in type 1 papillary renal cell carcinoma WP4205,0.4823229150860402,1.1717000781046603,0.8543350832933985,"['CDKN1A', 'JAK3', 'PAK5']",0.7859093397742131,0,0,3
215,Metapathway biotransformation Phase I and II WP702,0.4823229150860402,1.1717000781046603,0.8543350832933985,"['FMO5', 'GAL3ST4', 'HS6ST3']",0.7859093397742131,0,0,3
216,Hepatitis B infection WP4666,0.490298659355817,1.0779518072289156,0.7682999797639919,"['CDKN1A', 'TICAM2', 'CYCS', 'IKBKE', 'JAK3', 'MAP2K6']",0.7859093397742131,0,0,6
217,Insulin Signaling WP481,0.49165684717361635,1.0657674862735735,0.756667494043757,"['PTPN1', 'XBP1', 'ENPP1', 'MAP3K8', 'PRKCQ', 'SH2B2', 'MAP2K6']",0.7859093397742131,0,0,7
218,Amyotrophic lateral sclerosis (ALS) WP2447,0.4923730763252707,1.2389064431927463,0.8777882148403492,"['CASP1', 'MAP2K6']",0.7859093397742131,0,0,2
219,CAMKK2  Pathway WP4874,0.4923730763252707,1.2389064431927463,0.8777882148403492,"['CHRM3', 'HMOX1']",0.7859093397742131,0,0,2
220,Sleep regulation WP3591,0.5059993658763877,1.496852220013254,1.0196854641052413,['PER3'],0.7859093397742131,0,0,1
221,Transcription factor regulation in adipogenesis WP3599,0.5059993658763877,1.496852220013254,1.0196854641052413,['CEBPB'],0.7859093397742131,0,0,1
222,Type II diabetes mellitus WP1584,0.5059993658763877,1.496852220013254,1.0196854641052413,['GK'],0.7859093397742131,0,0,1
223,Ebstein-Barr virus LMP1 signaling WP262,0.5059993658763877,1.496852220013254,1.0196854641052413,['HSP90AA1'],0.7859093397742131,0,0,1
224,Mitochondrial complex III assembly WP4921,0.5059993658763877,1.496852220013254,1.0196854641052413,['UQCRQ'],0.7859093397742131,0,0,1
225,NAD+ biosynthetic pathways WP3645,0.5059993658763877,1.496852220013254,1.0196854641052413,['NAMPT'],0.7859093397742131,0,0,1
226,Androgen receptor signaling pathway WP138,0.5202745819577204,1.0722388059701493,0.7005992966708945,"['CDKN1A', 'LIMK2', 'CALR', 'FKBP4']",0.7859093397742131,0,0,4
227,ErbB signaling pathway WP673,0.5202745819577204,1.0722388059701493,0.7005992966708945,"['CDKN1A', 'NRG3', 'NRG1', 'PAK5']",0.7859093397742131,0,0,4
228,G Protein Signaling Pathways WP35,0.5202745819577204,1.0722388059701493,0.7005992966708945,"['GNA13', 'PDE4B', 'PRKCQ', 'PRKD1']",0.7859093397742131,0,0,4
229,Cholesterol metabolism (includes both Bloch and Kandutsch-Russell pathways) WP4718,0.5260083572141456,1.1587199588741808,0.7444059393429513,"['ACSL1', 'ELOVL5']",0.7859093397742131,0,0,2
230,Common Pathways Underlying Drug Addiction WP2636,0.5260083572141456,1.1587199588741808,0.7444059393429513,"['GRM5', 'GRM1']",0.7859093397742131,0,0,2
231,Thermogenesis WP4321,0.5314246448511268,1.0563529411764705,0.667819853459657,"['CPT1A', 'ACSL1', 'MGLL', 'FGFR1']",0.7859093397742131,0,0,4
232,1q21.1 copy number variation syndrome WP4905,0.5321029240964219,1.3815568129683438,0.8716495338251294,['FMO5'],0.7859093397742131,0,0,1
233,Striated Muscle Contraction Pathway WP383,0.5321029240964219,1.3815568129683438,0.8716495338251294,['MYOM1'],0.7859093397742131,0,0,1
234,Triacylglyceride synthesis WP325,0.5321029240964219,1.3815568129683438,0.8716495338251294,['GK'],0.7859093397742131,0,0,1
235,Heart Development WP1591,0.5321029240964219,1.3815568129683438,0.8716495338251294,['VEGFA'],0.7859093397742131,0,0,1
236,IL-9 signaling pathway WP22,0.5321029240964219,1.3815568129683438,0.8716495338251294,['JAK3'],0.7859093397742131,0,0,1
237,Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells WP4301,0.5321029240964219,1.3815568129683438,0.8716495338251294,['RAB27A'],0.7859093397742131,0,0,1
238,MFAP5 effect on permeability and motility of endothelial cells via cytoskeleton rearrangement WP4560,0.5321029240964219,1.3815568129683438,0.8716495338251294,['PRKCQ'],0.7859093397742131,0,0,1
239,Purine metabolism and related disorders WP4224,0.5321029240964219,1.3815568129683438,0.8716495338251294,['GRM5'],0.7859093397742131,0,0,1
240,Non-small cell lung cancer WP4255,0.5354435057326372,1.0774850299401197,0.6730616833225775,"['CDKN1A', 'CYCS', 'JAK3']",0.7875481563484207,0,0,3
241,Osteoblast differentiation WP4787,0.5482349212143768,1.0562404602559587,0.6348548026703835,"['PRKCQ', 'PRKD1', 'FGFR1']",0.7990280251114256,0,0,3
242,Ebola Virus Pathway on Host WP4217,0.548308896764766,1.0201083986154127,0.6129999385401534,"['BST2', 'HLA-DRB5', 'SCIN', 'IKBKE', 'HLA-DPA1']",0.7990280251114256,0,0,5
243,Breast cancer pathway WP4262,0.5533329174954367,1.025942857142857,0.6071483023152199,"['CDKN1A', 'FGF20', 'IGF1', 'FGFR1']",0.7990280251114256,0,0,4
244,Overview of interferons-mediated signaling pathway WP4558,0.5568297285479056,1.282732178358421,0.7510342767841669,['IFNAR2'],0.7990280251114256,0,0,1
245,Oxysterols derived from cholesterol WP4545,0.5568297285479056,1.282732178358421,0.7510342767841669,['ACOT11'],0.7990280251114256,0,0,1
246,Photodynamic therapy-induced NF-kB survival signaling WP3617,0.5568297285479056,1.282732178358421,0.7510342767841669,['VEGFA'],0.7990280251114256,0,0,1
247,FBXL10 enhancement of MAP/ERK signaling in diffuse large B-cell lymphoma WP4553,0.5802522551414419,1.1970841616964878,0.6515637483278812,['BCL6'],0.822606610702526,0,0,1
248,FGFR3 signaling in chondrocyte proliferation and terminal differentiation WP4767,0.5802522551414419,1.1970841616964878,0.6515637483278812,['CDKN1A'],0.822606610702526,0,0,1
249,Gastric Cancer Network 2 WP2363,0.5802522551414419,1.1970841616964878,0.6515637483278812,['RNF144B'],0.822606610702526,0,0,1
250,Head and Neck Squamous Cell Carcinoma WP4674,0.5853359978601991,0.9972277666888445,0.534084518421389,"['CDKN1A', 'VEGFA', 'FGFR1']",0.826494428978601,0,0,3
251,Exercise-induced Circadian Regulation WP410,0.5886271215666942,1.025839499146272,0.543656328257039,"['CEBPB', 'ERC2']",0.8278301749523628,0,0,2
252,Alzheimer's disease WP2059,0.5972632109237964,0.978987479586282,0.5045675756026421,"['CYCS', 'CACNA1C', 'APOE']",0.836642513714683,0,0,3
253,Vitamin D in inflammatory diseases WP4482,0.6024391716092413,1.1221421471172963,0.5686663809926419,['MAP2K6'],0.8372481400711109,0,0,1
254,Nuclear receptors WP170,0.6024391716092413,1.1221421471172963,0.5686663809926419,['RORA'],0.8372481400711109,0,0,1
255,Synaptic signaling pathways associated with autism spectrum disorder WP4539,0.6175555201086987,0.9701733606116076,0.4676102717524713,"['CACNA1C', 'GRM1']",0.8515511663998854,0,0,2
256,T-Cell antigen Receptor (TCR) pathway during Staphylococcus aureus infection WP3863,0.6175555201086987,0.9701733606116076,0.4676102717524713,"['MAP3K8', 'PRKCQ']",0.8515511663998854,0,0,2
257,MTHFR deficiency WP4288,0.6234555373493872,1.0560168401356567,0.4989445427402667,['CYCS'],0.8526151387627513,0,0,1
258,PKC-gamma calcium signaling pathway in ataxia WP4760,0.6234555373493872,1.0560168401356567,0.4989445427402667,['GRM1'],0.8526151387627513,0,0,1
259,DNA damage response WP707,0.6314232643142529,0.9445376389180121,0.43427843689665135,"['CDKN1A', 'CYCS']",0.8526151387627513,0,0,2
260,Corticotropin-releasing hormone signaling pathway WP2355,0.6316786275439185,0.9280404707825728,0.42631814106149296,"['HSP90AA1', 'PRKCQ', 'JUNB']",0.8526151387627513,0,0,3
261,Nanoparticle triggered autophagic cell death WP2509,0.6433629925404387,0.9972387894853103,0.43982836305765094,['ATG14'],0.8526151387627513,0,0,1
262,Neovascularisation processes WP4331,0.6433629925404387,0.9972387894853103,0.43982836305765094,['HIF1A'],0.8526151387627513,0,0,1
263,Gastrin signaling pathway WP4659,0.6446415514792379,0.9081518987341772,0.39873394531798045,"['CDKN1A', 'PRKCQ', 'PRKD1', 'VEGFA']",0.8526151387627513,0,0,4
264,Selenium Micronutrient Network WP15,0.6448958698290499,0.92021656961896,0.4036681057763022,"['PLAT', 'ALOX15B']",0.8526151387627513,0,0,2
265,Synaptic Vesicle Pathway WP2267,0.6448958698290499,0.92021656961896,0.4036681057763022,"['CACNA1B', 'SYN3']",0.8526151387627513,0,0,2
266,miRNA regulation of DNA damage response WP1530,0.6448958698290499,0.92021656961896,0.4036681057763022,"['CDKN1A', 'CYCS']",0.8526151387627513,0,0,2
267,p53 transcriptional gene network WP4963,0.6448958698290499,0.92021656961896,0.4036681057763022,"['CDKN1A', 'DRAM1']",0.8526151387627513,0,0,2
268,EGFR Tyrosine Kinase Inhibitor Resistance WP4806,0.6534632276828868,0.8969061876247505,0.3816057942638085,"['NRG1', 'IGF1', 'VEGFA']",0.8562770622649398,0,0,3
269,Translation inhibitors in chronically activated PDGFRA cells WP4566,0.6579763382942625,0.8971115537848605,0.3755186134702199,"['PIM1', 'MAP2K6']",0.8562770622649398,0,0,2
270,Type II interferon signaling (IFNG) WP619,0.6622199376723189,0.9446479020613163,0.38934376123132797,['OAS1'],0.8562770622649398,0,0,1
271,Fatty Acid Biosynthesis WP357,0.6622199376723189,0.9446479020613163,0.38934376123132797,['ACSL1'],0.8562770622649398,0,0,1
272,IL-7 signaling pathway WP205,0.6622199376723189,0.9446479020613163,0.38934376123132797,['JAK3'],0.8562770622649398,0,0,1
273,IL17 signaling pathway WP2112,0.6622199376723189,0.9446479020613163,0.38934376123132797,['CEBPB'],0.8562770622649398,0,0,1
274,Pathogenic Escherichia coli infection WP2272,0.6706684540651832,0.8751336118938878,0.34959870024014084,"['LY96', 'CD14']",0.8640363660036848,0,0,2
275,TLR4 Signaling and Tolerance WP3851,0.6800817032820963,0.8973161033797217,0.3459533467568361,['IKBKE'],0.8690186949628683,0,0,1
276,Intracellular trafficking proteins involved in CMT neuropathy WP4856,0.6800817032820963,0.8973161033797217,0.3459533467568361,['HSPB1'],0.8690186949628683,0,0,1
277,Endometrial cancer WP4155,0.6829766934869633,0.85420223866439,0.32570265284600686,"['CDKN1A', 'FGFR1']",0.8690186949628683,0,0,2
278,Pancreatic adenocarcinoma pathway WP4263,0.6843829948999359,0.8539112251687102,0.3238352299834083,"['CDKN1A', 'PAK5', 'VEGFA']",0.8690186949628683,0,0,3
279,3q29 copy number variation syndrome WP4906,0.6949061416882326,0.8342444176781247,0.30364702382762127,"['HIF1A', 'HAMP']",0.8694037140534875,0,0,2
280,Interferon type I signaling pathways WP585,0.6949061416882326,0.8342444176781247,0.30364702382762127,"['IFNAR2', 'MAP2K6']",0.8694037140534875,0,0,2
281,Signal transduction through IL1R WP4496,0.697000711266677,0.8544920950487551,0.3084450269641753,['MAP2K6'],0.8694037140534875,0,0,1
282,Glycerophospholipid Biosynthetic Pathway WP2533,0.697000711266677,0.8544920950487551,0.3084450269641753,['GK'],0.8694037140534875,0,0,1
283,SARS-CoV-2 mitochondrial interactions WP5038,0.697000711266677,0.8544920950487551,0.3084450269641753,['IKBKE'],0.8694037140534875,0,0,1
284,Small cell lung cancer WP4658,0.706462416036497,0.8151937703730533,0.2832678320251209,"['CDKN1A', 'CYCS']",0.8781029326087445,0,0,2
285,Epithelial to mesenchymal transition in colorectal cancer WP4239,0.7223431478081367,0.8025739565644829,0.2610411754073679,"['PROX1', 'HIF1A', 'MAP2K6']",0.8898044855313181,0,0,3
286,GABA receptor Signaling WP4159,0.7282065053668493,0.7800155588209872,0.24739801043810106,['GABRG3'],0.8898044855313181,0,0,1
287,Parkinson's disease pathway WP2371,0.7282065053668493,0.7800155588209872,0.24739801043810106,['CYCS'],0.8898044855313181,0,0,1
288,Regucalcin in proximal tubule epithelial kidney cells WP4838,0.7282065053668493,0.7800155588209872,0.24739801043810106,['PRKCQ'],0.8898044855313181,0,0,1
289,AGE/RAGE pathway WP2324,0.7284801595426371,0.7795773428027022,0.24696611730308576,"['CYCS', 'HIF1A']",0.8898044855313181,0,0,2
290,Retinoblastoma gene in cancer WP2446,0.738954922948145,0.7629058235144528,0.23079301647227546,"['CDKN1A', 'SAP30']",0.8994865096575697,0,0,2
291,Folate Metabolism WP176,0.7425849254248534,0.7474320742213386,0.22244926684716312,['PLAT'],0.900798895790286,0,0,1
292,Kit receptor signaling pathway WP304,0.7490829889136844,0.7469289508632138,0.21579188349627038,"['JUNB', 'SH2B2']",0.9018245110068202,0,0,2
293,ATM Signaling Pathway WP2516,0.7562041225439625,0.717455268389662,0.2004885240180285,['CDKN1A'],0.9018245110068202,0,0,1
294,Kisspeptin/kisspeptin receptor system in the ovary WP4871,0.7562041225439625,0.717455268389662,0.2004885240180285,['PRKCQ'],0.9018245110068202,0,0,1
295,miRNA regulation of prostate cancer signaling pathways WP3981,0.7562041225439625,0.717455268389662,0.2004885240180285,['CDKN1A'],0.9018245110068202,0,0,1
296,Neural Crest Cell Migration during Development WP4564,0.7562041225439625,0.717455268389662,0.2004885240180285,['PAK5'],0.9018245110068202,0,0,1
297,TGF-beta Signaling Pathway WP366,0.7603206266681044,0.770236559139785,0.21105641501976155,"['CDKN1A', 'LIMK2', 'JUNB', 'MAP2K6']",0.903680744827747,0,0,4
298,Chromosomal and microsatellite instability in colorectal cancer  WP4216,0.7683285760336459,0.7168924302788845,0.18892825674545624,"['CDKN1A', 'CYCS']",0.9080058559932245,0,0,2
299,MAPK Cascade WP422,0.769104110317207,0.6897843706988837,0.18108835595193584,['MAP2K6'],0.9080058559932245,0,0,1
300,Nonalcoholic fatty liver disease WP4396,0.7724800791602061,0.7714567065164812,0.19915082210403315,"['XBP1', 'UQCRQ', 'LEPR', 'CYCS', 'COX7A1']",0.9089515598118426,0,0,5
301,Acute viral myocarditis WP4298,0.7774613105128636,0.7027575970627294,0.17689912448214518,"['CASP1', 'CYCS']",0.9102539522531548,0,0,2
302,Mitochondrial CIV Assembly WP4922,0.7813227975430762,0.664163169133348,0.16389348728263303,['SCO2'],0.9102539522531548,0,0,1
303,Prader-Willi and Angelman Syndrome WP3998,0.7813227975430762,0.664163169133348,0.16389348728263303,['GABRG3'],0.9102539522531548,0,0,1
304,Thyroid stimulating hormone (TSH) signaling pathway WP2032,0.786277696673175,0.6891664112779651,0.16570678680848244,"['GNA13', 'MAP2K6']",0.9130132464658907,0,0,2
305,mBDNF and proBDNF regulation of GABA neurotransmission WP4829,0.7928960985839808,0.6403720533939222,0.14860671691900165,['GABRG3'],0.9146807934645268,0,0,1
306,Neural Crest Cell Migration in Cancer WP4565,0.7928960985839808,0.6403720533939222,0.14860671691900165,['PAK5'],0.9146807934645268,0,0,1
307,TGF-beta Receptor Signaling WP560,0.8142408509148992,0.5975480450629556,0.12279556819822685,['SPP1'],0.9284702273233195,0,0,1
308,Integrated Cancer Pathway WP1971,0.8142408509148992,0.5975480450629556,0.12279556819822685,['CDKN1A'],0.9284702273233195,0,0,1
309,Phosphodiesterases in neuronal function WP4222,0.8142408509148992,0.5975480450629556,0.12279556819822685,['PDE4B'],0.9284702273233195,0,0,1
310,Wnt signaling pathway and pluripotency WP399,0.8185379221928459,0.6396556630620376,0.12808180472887049,"['PRKCQ', 'PRKD1']",0.9284702273233195,0,0,2
311,Glycogen Synthesis and Degradation WP500,0.8240750746128769,0.5782081703328417,0.11187960543799641,['PYGL'],0.9284702273233195,0,0,1
312,Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms WP4534,0.8240750746128769,0.5782081703328417,0.11187960543799641,['PAK5'],0.9284702273233195,0,0,1
313,SARS-CoV-2 innate immunity evasion and cell-specific immune response WP5039,0.8240750746128769,0.5782081703328417,0.11187960543799641,['IFNAR2'],0.9284702273233195,0,0,1
314,Prolactin Signaling Pathway WP2037,0.8258913636813663,0.6283637380303349,0.12020097821683383,"['PTPN1', 'PPIB']",0.9284702273233195,0,0,2
315,Focal Adhesion WP306,0.8289153220270011,0.687923076923077,0.12908001072702457,"['FGR', 'SPP1', 'IGF1', 'VEGFA']",0.9289114561127981,0,0,4
316,IL-2 signaling pathway WP49,0.8333896400778628,0.5600770377733598,0.10207627539220976,['JAK3'],0.9309700726186252,0,0,1
317,Eukaryotic Transcription Initiation WP405,0.8422119551109818,0.5430447617326345,0.09325358420838954,['POLR2K'],0.932454964926709,0,0,1
318,G1 to S cell cycle control WP45,0.8422119551109818,0.5430447617326345,0.09325358420838954,['CDKN1A'],0.932454964926709,0,0,1
319,Integrin-mediated Cell Adhesion WP185,0.8463699903403408,0.5967463479415671,0.0995364996427242,"['ITGAX', 'MAP2K6']",0.932454964926709,0,0,2
320,TGF-beta receptor signaling in skeletal dysplasias WP4816,0.8505679850039668,0.5270143842825401,0.08529777085671691,['SPP1'],0.932454964926709,0,0,1
321,IL-6 signaling pathway WP364,0.8505679850039668,0.5270143842825401,0.08529777085671691,['JUNB'],0.932454964926709,0,0,1
322,Neural Crest Differentiation WP2064,0.8505679850039668,0.5270143842825401,0.08529777085671691,['FGFR1'],0.932454964926709,0,0,1
323,Splicing factor NOVA regulated synaptic proteins WP4148,0.8584823277026998,0.5119000284010224,0.07811040759442359,['EPB41L3'],0.9327688973078346,0,0,1
324,T-cell receptor (TCR) signaling pathway WP69,0.8587815626771848,0.5773679475645804,0.08789889005122355,"['MAP3K8', 'PRKCQ']",0.9327688973078346,0,0,2
325,Leptin signaling pathway WP2034,0.8587815626771848,0.5773679475645804,0.08789889005122355,"['PTPN1', 'LEPR']",0.9327688973078346,0,0,2
326,Primary focal segmental glomerulosclerosis (FSGS) WP2572,0.865978286097507,0.4976253589573669,0.07160602223381539,['CDKN1A'],0.9377004140871779,0,0,1
327,ATM Signaling Network in Development and Disease  WP3878,0.8730779360075411,0.4841222932674225,0.0657101383420043,['HSPB1'],0.9396235103983598,0,0,1
328,Genotoxicity pathway WP4286,0.8730779360075411,0.4841222932674225,0.0657101383420043,['CDKN1A'],0.9396235103983598,0,0,1
329,Mesodermal commitment pathway WP2857,0.8859013252416441,0.53398346910864,0.06469194009826494,"['TRERF1', 'FGFR1']",0.9443346866664237,0,0,2
330,Novel intracellular components of RIG-I-like receptor (RLR) pathway WP3865,0.8861708615535666,0.4591935566090636,0.055491475391629325,['IKBKE'],0.9443346866664237,0,0,1
331,Cell cycle WP179,0.8907118459569626,0.5260721818607921,0.060884600467095935,"['ANAPC13', 'CDKN1A']",0.9443346866664237,0,0,2
332,Chemokine signaling pathway WP3929,0.8927203659682379,0.5703274302458912,0.06472183308192328,"['FGR', 'CX3CR1', 'JAK3']",0.9443346866664237,0,0,3
333,Copper homeostasis WP3286,0.8979155360727887,0.4366968918198128,0.04702320380153537,['SCO2'],0.9443346866664237,0,0,1
334,DNA damage response (only ATM dependent) WP710,0.8997733098158365,0.5109277177006261,0.053960315453495424,"['CDKN1A', 'BCL6']",0.9443346866664237,0,0,2
335,IL-3 signaling pathway WP286,0.9033261616161515,0.4262520117390893,0.04333772104372996,['IL3RA'],0.9443346866664237,0,0,1
336,"Non-genomic actions of 1,25 dihydroxyvitamin D3 WP4341",0.9033261616161515,0.4262520117390893,0.04333772104372996,['PRKCQ'],0.9443346866664237,0,0,1
337,RANKL/RANK signaling pathway WP2018,0.9033261616161515,0.4262520117390893,0.04333772104372996,['MAP2K6'],0.9443346866664237,0,0,1
338,Angiopoietin Like Protein 8 Regulatory Pathway WP3915,0.9042071504058109,0.5525032409407988,0.055635306231591825,"['PTPN1', 'MAP3K8', 'MAP2K6']",0.9443346866664237,0,0,3
339,IL-1 signaling pathway WP195,0.9222534808238415,0.3890137436252053,0.03148489278753455,['MAP2K6'],0.9575161139141649,0,0,1
340,Mitochondrial complex I assembly model OXPHOS system WP4324,0.9222534808238415,0.3890137436252053,0.03148489278753455,['TMEM70'],0.9575161139141649,0,0,1
341,22q11.2 copy number variation syndrome WP4657,0.9339787895812824,0.3650748569805656,0.024935178685018,['FGFR1'],0.9648127179585043,0,0,1
342,B Cell Receptor Signaling Pathway WP23,0.9354583776772387,0.4465637450199203,0.029794119631359976,"['BCL6', 'MAP2K6']",0.9648127179585043,0,0,2
343,Melanoma WP4685,0.9374809129171868,0.3577335984095427,0.02309488077358944,['CDKN1A'],0.9648127179585043,0,0,1
344,DNA IR-damage and cellular response via ATR WP4016,0.9439386712977869,0.34389814956415354,0.01984088796929115,['BCL6'],0.9657389982940476,0,0,1
345,Electron Transport Chain (OXPHOS system in mitochondria) WP111,0.9460437834975747,0.42510908745968506,0.023579282691323193,"['UQCRQ', 'COX7A1']",0.9657389982940476,0,0,2
346,Ras signaling WP4223,0.9465883665998314,0.47770530367835756,0.026221698537972942,"['KSR2', 'PAK5', 'FGFR1']",0.9657389982940476,0,0,3
347,16p11.2 proximal deletion syndrome WP4949,0.9617296650942994,0.30286080129393134,0.011818198215372557,['MAP2K6'],0.9783589964792153,0,0,1
348,7q11.23 copy number variation syndrome WP4932,0.9790070799077332,0.25495597841522294,0.005409249219447421,['NRG1'],0.9915988453335627,0,0,1
349,Integrated breast cancer pathway WP1984,0.9803625977943722,0.33605201834172743,0.006664845076373961,"['MAP3K7CL', 'VEGFA']",0.9915988453335627,0,0,2
350,Endoderm differentiation WP2853,0.9840252057396123,0.23782637508283633,0.003829900452049132,['TRERF1'],0.9924597075030948,0,0,1
351,Brain-derived neurotrophic factor (BDNF) signaling pathway WP2380,0.9888518360926329,0.3014720777905328,0.0033797342521258112,"['SPP1', 'SH2B2']",0.9944863194891721,0,0,2
352,EGF/EGFR signaling pathway WP437,0.9937238448799574,0.2732761262641741,0.0017205281753416553,"['PLSCR1', 'LIMK2']",0.99654692398473,0,0,2
353,Ciliary landscape WP4352,0.9998829814511588,0.10701849509006567,1.2523881772132063e-05,['IQGAP2'],0.9998829814511588,0,0,1
